Pathophysiology of autism spectrum disorders: Revisiting gastrointestinal involvement and immune imbalance

World Journal of Gastroenterology

Volumn , Issue 29, 2014, Pages 9942-9951

  Samsam, Mohtashem ^a   Ahangari, Raheleh ^a   Naser, Saleh A ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Autism spectrum disorders; Brain derived neurotrophic factor; Crohn's disease; Gastrointestinal abnormalities; Immune activation; Mycobacterium paratuberculosis; Neuropeptides

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCITONIN GENE RELATED PEPTIDE; CARDIOLIPIN ANTIBODY; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NEUROTROPHIN; OLCEGEPANT; PHOSPHOLIPID ANTIBODY; TELCAGEPANT; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOCONSTRICTOR AGENT; NEUROPEPTIDE; NEUROTROPHIN 4; PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AUTISM; AUTOIMMUNE DISEASE; CHRONIC DIARRHEA; CONSTIPATION; CROHN DISEASE; DISEASE ASSOCIATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GENDER; GENE; GENE EXPRESSION; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INTESTINE FLORA; INTESTINE INFECTION; INTESTINE LYMPHATIC TISSUE; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; MATERNAL DISEASE; MIGRAINE; NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; REVIEW; SYNAPTOGENESIS; TH1 TH2 BALANCE; VOMITING; COMPLICATION; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HOMEOSTASIS; IMMUNE SYSTEM; IMMUNOLOGY; PROGNOSIS; RISK FACTOR; ADAPTIVE IMMUNITY; ALLELE; ANTIGEN PRESENTING CELL; BACTERIAL IMMUNITY; BRAIN REGION; CHILDHOOD DISEASE; GASTROINTESTINAL SYMPTOM; GENE CONTROL; GENETIC ASSOCIATION; IMMUNE DYSREGULATION; NEUROIMAGING; PATHOGENESIS; REGULATORY T LYMPHOCYTE; SEX RATIO; X CHROMOSOME INACTIVATION;

CHILD DEVELOPMENT DISORDERS, PERVASIVE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HOMEOSTASIS; HUMANS; IMMUNE SYSTEM; PROGNOSIS; RISK FACTORS;

EID: 84905836819     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i29.9942     Document Type: Review

References (117)

1. Lauritsen MB. Autism spectrum disorders. Eur Child Adolesc Psychiatry 2013; 22 Suppl 1: S37-S42 [PMID: 23300017 DOI: 10.1007/s00787-012-0359-5]
2. Grzadzinski R, Huerta M, Lord C. DSM-5 and autism spectrum disorders (ASDs): an opportunity for identifying ASD subtypes. Mol Autism 2013; 4: 12 [PMID: 23675638 DOI: 10.1186/2040-2392-4-12]
3. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 2012; 61: 1-19 [PMID: 22456193]
4. Maenner MJ, Rice CE, Arneson CL, Cunniff C, Schieve LA, Carpenter LA, Van Naarden Braun K, Kirby RS, Bakian AV, Durkin MS. Potential impact of DSM-5 criteria on autism spectrum disorder prevalence estimates. JAMA Psychiatry 2014; 71: 292-300 [PMID: 24452504 DOI: 10.1001/jamapsychiatry.2013.3893]
5. Shen Y, Dies KA, Holm IA, Bridgemohan C, Sobeih MM, Caronna EB, Miller KJ, Frazier JA, Silverstein I, Picker J, Weissman L, Raffalli P, Jeste S, Demmer LA, Peters HK, Brewster SJ, Kowalczyk SJ, Rosen-Sheidley B, McGowan C, Duda AW, Lincoln SA, Lowe KR, Schonwald A, Robbins M, Hisama F, Wolff R, Becker R, Nasir R, Urion DK, Milunsky JM, Rappaport L, Gusella JF, Walsh CA, Wu BL, Miller DT. Clinical genetic testing for patients with autism spectrum disorders. Pediatrics 2010; 125: e727-e735 [PMID: 20231187 DOI: 10.1542/peds.2009-1684]
6. Silver WG, Rapin I. Neurobiological basis of autism. Pediatr Clin North Am 2012; 59: 45-61, x [PMID: 22284792 DOI: 10.1016/j.pcl.2011.10.010]
7. Betancur C, Sakurai T, Buxbaum JD. The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci 2009; 32: 402-412 [PMID: 19541375 DOI: 10.1016/j.tins.2009.04.003]
8. White JF. Intestinal pathophysiology in autism. Exp Biol Med (Maywood) 2003; 228: 639-649 [PMID: 12773694]
9. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 1995; 25: 63-77 [PMID: 7792363]
10. Bruining H, de Sonneville L, Swaab H, de Jonge M, Kas M, van Engeland H, Vorstman J. Dissecting the clinical heterogeneity of autism spectrum disorders through defined genotypes. PLoS One 2010; 5: e10887 [PMID: 20526357 DOI: 10.1371/journal.pone.0010887]
11. Shinoda Y, Sadakata T, Furuichi T. Animal models of autism spectrum disorder (ASD): a synaptic-level approach to autistic-like behavior in mice. Exp Anim 2013; 62: 71-78 [PMID: 23615300]
12. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T, Yamrom B, Yoon S, Krasnitz A, Kendall J, Leotta A, Pai D, Zhang R, Lee YH, Hicks J, Spence SJ, Lee AT, Puura K, Lehtimäki T, Ledbetter D, Gregersen PK, Bregman J, Sutcliffe JS, Jobanputra V, Chung W, Warburton D, King MC, Skuse D, Geschwind DH, Gilliam TC, Ye K, Wigler M. Strong association of de novo copy number mutations with autism. Science 2007; 316: 445-449 [PMID: 17363630]
13. Mikhail FM, Lose EJ, Robin NH, Descartes MD, Rutledge KD, Rutledge SL, Korf BR, Carroll AJ. Clinically relevant single gene or intragenic deletions encompassing critical neurodevelopmental genes in patients with developmental delay, mental retardation, and/or autism spectrum disorders. Am J Med Genet A 2011; 155A: 2386-2396 [PMID: 22031302 DOI: 10.1002/ajmg.a.34177]
14. Ronemus M, Iossifov I, Levy D, Wigler M. The role of de novo mutations in the genetics of autism spectrum disorders. Nat Rev Genet 2014; 15: 133-141 [PMID: 24430941 DOI: 10.1038/nrg3585]
15. Malhotra D, Sebat J. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell 2012; 148: 1223-1241 [PMID: 22424231 DOI: 10.1016/j.cell.2012.02.039]
16. Zoghbi HY, Bear MF. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb Perspect Biol 2012; 4: [PMID: 22258914 DOI: 10.1101/cshperspect.a009886]
17. Banerjee S, Riordan M, Bhat MA. Genetic aspects of autism spectrum disorders: insights from animal models. Front Cell Neurosci 2014; 8: 58 [PMID: 24605088 DOI: 10.3389/fncel.2014.00058]
18. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics 2004; 113: e472-e486 [PMID: 15121991]
19. Betancur C. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res 2011; 1380: 42-77 [PMID: 21129364 DOI: 10.1016/j.brainres.2010.11.078]
20. Miles JH. Autism spectrum disorders - a genetics review. Genet Med 2011; 13: 278-294 [PMID: 21358411 DOI: 10.1097/GIM.0b013e3181ff67ba]
21. Jyonouchi H, Geng L, Streck DL, Toruner GA. Immunological characterization and transcription profiling of peripheral blood (PB) monocytes in children with autism spectrum disorders (ASD) and specific polysaccharide antibody deficiency (SPAD): case study. J Neuroinflammation 2012; 9: 4 [PMID: 22226452 DOI: 10.1186/1742-2094-9-4]
22. Álvarez-Iglesias V, Mosquera-Miguel A, Cuscó I, Carracedo Á, Pérez-Jurado LA, Salas A. Reassessing the role of mitochondrial DNA mutations in autism spectrum disorder. BMC Med Genet 2011; 12: 50 [PMID: 21470425 DOI: 10.1186/1471-2350-12-50]
23. Knott AB, Bossy-Wetzel E. Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration. Ann N Y Acad Sci 2008; 1147: 283-292 [PMID: 19076450 DOI: 10.1196/annals.1427.030]
24. Randolph-Gips M, Srinivasan P. Modeling autism: a systems biology approach. J Clin Bioinforma 2012; 2: 17 [PMID: 23043674 DOI: 10.1186/2043-9113-2-17]
25. West AP, Shadel GS, Ghosh S. Mitochondria in innate immune responses. Nat Rev Immunol 2011; 11: 389-402 [PMID: 21597473 DOI: 10.1038/nri2975]
26. Schaafsma SM, Pfaff DW. Etiologies underlying sex differences in Autism Spectrum Disorders. Front Neuroendocrinol 2014; 35: 255-271 [PMID: 24705124 DOI: 10.1016/j.yfrne.2014.03.006]
27. Ben-David E, Shohat S, Shifman S. Allelic expression analysis in the brain suggests a role for heterogeneous insults affecting epigenetic processes in autism spectrum disorders. Hum Mol Genet 2014; 23: 4111-4124 [PMID: 24659497]
28. Gabory A, Roseboom TJ, Moore T, Moore LG, Junien C. Placental contribution to the origins of sexual dimorphism in health and diseases: sex chromosomes and epigenetics. Biol Sex Differ 2013; 4: 5 [PMID: 23514128 DOI: 10.1186/2042-6410-4-5]
29. Santangelo SL, Tsatsanis K. What is known about autism: genes, brain, and behavior. Am J Pharmacogenomics 2005; 5: 71-92 [PMID: 15813671]
30. Casanova MF, El-Baz AS, Kamat SS, Dombroski BA, Khalifa F, Elnakib A, Soliman A, Allison-McNutt A, Switala AE. Focal cortical dysplasias in autism spectrum disorders. Acta Neuropathol Commun 2013; 1: 67 [PMID: 24252498 DOI: 10.1186/2051-5960-1-67]
31. Casanova MF. Autism as a sequence: from heterochronic germinal cell divisions to abnormalities of cell migration and cortical dysplasias. Med Hypotheses 2014; 83: 32-38 [PMID: 24780284 DOI: 10.1016/j.mehy.2014.04.014]
32. Marchese M, Conti V, Valvo G, Moro F, Muratori F, Tancredi R, Santorelli FM, Guerrini R, Sicca F. Autism-epilepsy phenotype with macrocephaly suggests PTEN, but not GLIALCAM, genetic screening. BMC Med Genet 2014; 15: 26 [PMID: 24580998 DOI: 10.1186/1471-2350-15-26]
33. Black C, Kaye JA, Jick H. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. BMJ 2002; 325: 419-421 [PMID: 12193358 DOI: 10.1136/bmj.325.7361.419]
34. Buie T, Campbell DB, Fuchs GJ, Furuta GT, Levy J, Vandewater J, Whitaker AH, Atkins D, Bauman ML, Beaudet AL, Carr EG, Gershon MD, Hyman SL, Jirapinyo P, Jyonouchi H, Kooros K, Kushak R, Levitt P, Levy SE, Lewis JD, Murray KF, Natowicz MR, Sabra A, Wershil BK, Weston SC, Zeltzer L, Winter H. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics 2010; 125 Suppl 1: S1-18 [PMID: 20048083 DOI: 10.1542/peds.2009-1878C]
35. D'Eufemia P, Celli M, Finocchiaro R, Pacifico L, Viozzi L, Zaccagnini M, Cardi E, Giardini O. Abnormal intestinal permeability in children with autism. Acta Paediatr 1996; 85: 1076-1079 [PMID: 8888921 DOI: 10.1111/j.1651-2227.1996.tb14220.x]
36. Millward C, Ferriter M, Calver S, Connell-Jones G. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev 2008; 2: CD003498 [PMID: 18425890 DOI: 10.1002/14651858.CD003498.pub3]
37. Goodwin MS, Cowen MA, Goodwin TC. Malabsorption and cerebral dysfunction: a multivariate and comparative study of autistic children. J Autism Child Schizophr 1971; 1: 48-62 [PMID: 5172439 DOI: 10.1007/BF01537742]
38. Dohan FC. Hypothesis: genes and neuroactive peptides from food as cause of schizophrenia. Adv Biochem Psychopharmacol 1980; 22: 535-548 [PMID: 6994444]
39. Lightdale JR, Hayer C, Duer A, Lind-White C, Jenkins S, Siegel B, Elliott GR, Heyman MB. Effects of intravenous secretin on language and behavior of children with autism and gastrointestinal symptoms: a single-blinded, open-label pilot study. Pediatrics 2001; 108: E90 [PMID: 11694674 DOI: 10.1542/peds.108.5.e90]
40. Erickson CA, Stigler KA, Corkins MR, Posey DJ, Fitzgerald JF, McDougle CJ. Gastrointestinal factors in autistic disorder: a critical review. J Autism Dev Disord 2005; 35: 713-727 [PMID: 16267642 DOI: 10.1007/s10803-005-0019-4]
41. Hsiao EY. Gastrointestinal issues in autism spectrum disorder. Harv Rev Psychiatry 2014; 22: 104-111 [PMID: 24614765 DOI: 10.1097/HRP.0000000000000029]
42. Seltzer MM, Shattuck P, Abbeduto L, Greenberg JS. Trajectory of development in adolescents and adults with autism. Ment Retard Dev Disabil Res Rev 2004; 10: 234-247 [PMID: 15666341 DOI: 10.1002/mrdd.20038]
43. Goyal DK, Miyan JA. Neuro-immune abnormalities in autism and their relationship with the environment: a variable insult model for autism. Front Endocrinol (Lausanne) 2014; 5: 29 [PMID: 24639668]
44. Samsam M. Functionally Oriented Regional Anatomy. 2nd ed. Plymouth, MI: Hayden McNeil publishing, 2013: 209-302
45. Pastorelli L, De Salvo C, Mercado JR, Vecchi M, Pizarro TT. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol 2013; 4: 280 [PMID: 24062746]
46. Rabinowitz K, Mayer L. Working out mechanisms of controlled/physiologic inflammation in the GI tract. Immunol Res 2012; 54: 14-24 [PMID: 22466933 DOI: 10.1007/s12026-012-8315-5]
47. Kernéis S, Bogdanova A, Kraehenbuhl JP, Pringault E. Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria. Science 1997; 277: 949-952 [PMID: 9252325 DOI: 10.1126/science.277.5328.949]
48. Hemmings WA, Williams EW. Transport of large breakdown products of dietary protein through the gut wall. Gut 1978; 19: 715-723 [PMID: 680603 DOI: 10.1136/gut.19.8.715]
49. Dixon JB. Mechanisms of chylomicron uptake into lacteals. Ann N Y Acad Sci 2010; 1207 Suppl 1: E52-E57 [PMID: 20961306 DOI: 10.1111/j.1749-6632.2010.05716.x]
50. Lencer WI. Microbes and microbial Toxins: paradigms for microbial-mucosal toxins. V. Cholera: invasion of the intestinal epithelial barrier by a stably folded protein toxin. Am J Physiol Gastrointest Liver Physiol 2001; 280: G781-G786 [PMID: 11292584]
51. Limaye A, Koya V, Samsam M, Daniell H. Receptor-mediated oral delivery of a bioencapsulated green fluorescent protein expressed in transgenic chloroplasts into the mouse circulatory system. FASEB J 2006; 20: 959-961 [PMID: 16603603 DOI: 10.1096/fj.05-5134fje]
52. Ruhlman T, Ahangari R, Devine A, Samsam M, Daniell H. Expression of cholera toxin B-proinsulin fusion protein in lettuce and tobacco chloroplasts - oral administration protects against development of insulitis in non-obese diabetic mice. Plant Biotechnol J 2007; 5: 495-510 [PMID: 17490448 DOI: 10.1111/j.1467-7652.2007.00259.x]
53. Muanprasat C, Chatsudthipong V. Cholera: pathophysiology and emerging therapeutic targets. Future Med Chem 2013; 5: 781-798 [PMID: 23651092 DOI: 10.4155/fmc.13.42]
54. Enteropathogenic Escherichia coli Inhibits Type I Interferon- and RNase L-Mediated Host Defense To Disrupt Intestinal Epithelial Cell Barrier Function. Infect Immun 2014; 82: 2802-2814 [PMID: 24733098]
55. Wyatt J, Oberhuber G, Pongratz S, Püspök A, Moser G, Novacek G, Lochs H, Vogelsang H. Increased gastric and intestinal permeability in patients with Crohn's disease. Am J Gastroenterol 1997; 92: 1891-1896 [PMID: 9382060]
56. Meddings JB. Review article: Intestinal permeability in Crohn's disease. Aliment Pharmacol Ther 1997; 11 Suppl 3: 47-53; discussion 53-56 [PMID: 9467978 DOI: 10.1111/j.1365-2036.1997.tb00808.x]
57. Naser SA, Schwartz D, Shafran I. Isolation of Mycobacterium avium subsp paratuberculosis from breast milk of Crohn' s disease patients. Am J Gastroenterol 2000; 95: 1094-1095 [PMID: 10763975 DOI: 10.1111/j.1572-0241.2000.01954.x]
58. Naser SA, Ghobrial G, Romero C, Valentine JF. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet 2004; 364: 1039-1044 [PMID: 15380962 DOI: 10.1016/S0140-6736(04)17058-X]
59. Romero C, Hamdi A, Valentine JF, Naser SA. Evaluation of surgical tissue from patients with Crohn's disease for the presence of Mycobacterium avium subspecies paratuberculosis DNA by in situ hybridization and nested polymerase chain reaction. Inflamm Bowel Dis 2005; 11: 116-125 [PMID: 15677904 DOI: 10.1097/00054725-200502000-00004]
60. Dow CT. Mycobacterium paratuberculosis and autism: is this a trigger? Med Hypotheses 2011; 77: 977-981 [PMID: 21903338 DOI: 10.1016/j.mehy.2011.08.024]
61. Williams BL, Hornig M, Parekh T, Lipkin WI. Application of novel PCR-based methods for detection, quantitation, and phylogenetic characterization of Sutterella species in intestinal biopsy samples from children with autism and gastrointestinal disturbances. MBio 2012; 3: pii: e00261-11 [PMID: 22233678 DOI: 10.1128/mBio.00261-11]
62. Pequegnat B, Sagermann M, Valliani M, Toh M, Chow H, Allen-Vercoe E, Monteiro MA. A vaccine and diagnostic target for Clostridium bolteae, an autism-associated bacterium. Vaccine 2013; 31: 2787-2790 [PMID: 23602537 DOI: 10.1016/j.vaccine.2013.04.018]
63. Marques F, Brito MJ, Conde M, Pinto M, Moreira A. Autism spectrum disorder secondary to enterovirus encephalitis. J Child Neurol 2014; 29: 708-714 [PMID: 24782421 DOI: 10.1177/0883073813508314]
64. Ashwood P, Wills S, Van de Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol 2006; 80: 1-15 [PMID: 16698940 DOI: 10.1189/jlb.1205707]
65. Singh VK. Phenotypic expression of autoimmune autistic disorder (AAD): a major subset of autism. Ann Clin Psychiatry 2009; 21: 148-161 [PMID: 19758536]
66. Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry 2005; 17: 485-495 [PMID: 16401547 DOI: 10.1080/02646830500381930]
67. Samsam M. Editorial: central nervous system drugs in the treatment of neurological disorders. Cent Nerv Syst Agents Med Chem 2012; 12: 153-157 [PMID: 22894608]
68. Noriega DB, Savelkoul HF. Immune dysregulation in autism spectrum disorder. Eur J Pediatr 2014; 173: 33-43 [PMID: 24297668 DOI: 10.1007/s00431-013-2183-4]
69. Gupta S, Aggarwal S, Rashanravan B, Lee T. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. J Neuroimmunol 1998; 85: 106-109 [PMID: 9627004 DOI: 10.1016/S0165-5728(98)00021-6]
70. Molloy CA, Morrow AL, Meinzen-Derr J, Schleifer K, Dienger K, Manning-Courtney P, Altaye M, Wills-Karp M. Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol 2006; 172: 198-205 [PMID: 16360218 DOI: 10.1016/j.jneuroim.2005.11.007]
71. Croonenberghs J, Wauters A, Devreese K, Verkerk R, Scharpe S, Bosmans E, Egyed B, Deboutte D, Maes M. Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. Psychol Med 2002; 32: 1457-1463 [PMID: 12455944 DOI: 10.1017/S0033291702006037]
72. Kobsar I, Berghoff M, Samsam M, Wessig C, Mäurer M, Toyka KV, Martini R. Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1. Brain 2003; 126: 804-813 [PMID: 12615640 DOI: 10.1093/brain/awg072]
73. Samsam M. Role of inflammation in neurological and psychiatric disorders, editorial. AIAA-MC 2010; 3: 166-169
74. Berghoff M, Samsam M, Müller M, Kobsar I, Toyka KV, Kiefer R, Mäurer M, Martini R. Neuroprotective effect of the immune system in a mouse model of severe dysmyelinating hereditary neuropathy: enhanced axonal degeneration following disruption of the RAG-1 gene. Mol Cell Neurosci 2005; 28: 118-127 [PMID: 15607947 DOI: 10.1016/j.mcn.2004.09.001]
75. Allen T, Gundrajakuppam L. A role of immunotherapy in metastatic malignant melanoma. Cent Nerv Syst Agents Med Chem 2012; 12: 182-188 [PMID: 22697295]
76. Gesundheit B, Rosenzweig JP, Naor D, Lerer B, Zachor DA, Procházka V, Melamed M, Kristt DA, Steinberg A, Shulman C, Hwang P, Koren G, Walfisch A, Passweg JR, Snowden JA, Tamouza R, Leboyer M, Farge-Bancel D, Ashwood P. Immunological and autoimmune considerations of Autism Spectrum Disorders. J Autoimmun 2013; 44: 1-7 [PMID: 23867105 DOI: 10.1016/j.jaut.2013.05.005]
77. Goines PE, Ashwood P. Cytokine dysregulation in autism spectrum disorders (ASD): possible role of the environment. Neurotoxicol Teratol 2013; 36: 67-81 [PMID: 22918031 DOI: 10.1016/j.ntt.2012.07.006]
78. Sweeten TL, Bowyer SL, Posey DJ, Halberstadt GM, McDougle CJ. Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics 2003; 112: e420 [PMID: 14595086]
79. Sakić B, Szechtman H, Denburg JA. Neurobehavioral alterations in autoimmune mice. Neurosci Biobehav Rev 1997; 21: 327-340 [PMID: 9168268]
80. Libbey JE, Fujinami RS. Role for antibodies in altering behavior and movement. Autism Res 2010; 3: 147-152 [PMID: 20589715 DOI: 10.1002/aur.144]
81. Meyer U, Feldon J, Dammann O. Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res 2011; 69: 26R-33R [PMID: 21289540 DOI: 10.1203/PDR.0b013e318212c196]
82. Onore CE, Schwartzer JJ, Careaga M, Berman RF, Ashwood P. Maternal immune activation leads to activated inflammatory macrophages in offspring. Brain Behav Immun 2014; 38: 220-226 [PMID: 24566386 DOI: 10.1016/j.bbi.2014.02.007]
83. Lyall K, Ashwood P, Van de Water J, Hertz-Picciotto I. Maternal immune-mediated conditions, autism spectrum disorders, and developmental delay. J Autism Dev Disord 2014; 44: 1546-1555 [PMID: 24337796]
84. Careaga M, Hansen RL, Hertz-Piccotto I, Van de Water J, Ashwood P. Increased anti-phospholipid antibodies in autism spectrum disorders. Mediators Inflamm 2013; 2013: 935608 [PMID: 24174712 DOI: 10.1155/2013/935608]
85. Schwartzer JJ, Careaga M, Onore CE, Rushakoff JA, Berman RF, Ashwood P. Maternal immune activation and strain specific interactions in the development of autism-like behaviors in mice. Transl Psychiatry 2013; 3: e240 [PMID: 23481627 DOI: 10.1038/tp.2013.16]
86. Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tildon JT. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr 1999; 135: 559-563 [PMID: 10547242 DOI: 10.1016/S0022-3476(99)70052-1]
87. Williams BL, Hornig M, Buie T, Bauman ML, Cho Paik M, Wick I, Bennett A, Jabado O, Hirschberg DL, Lipkin WI. Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances. PLoS One 2011; 6: e24585 [PMID: 21949732 DOI: 10.1371/journal.pone.0024585]
88. Petrof EO, Claud EC, Gloor GB, Allen-Vercoe E. Microbial ecosystems therapeutics: a new paradigm in medicine? Benef Microbes 2013; 4: 53-65 [PMID: 23257018 DOI: 10.3920/BM2012.0039]
89. Kang DW, Park JG, Ilhan ZE, Wallstrom G, Labaer J, Adams JB, Krajmalnik-Brown R. Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLoS One 2013; 8: e68322 [PMID: 23844187 DOI: 10.1371/journal.pone.0068322]
90. Montiel-Castro AJ, González-Cervantes RM, Bravo-Ruiseco G, Pacheco-López G. The microbiota-gut-brain axis: neurobehavioral correlates, health and sociality. Front Integr Neurosci 2013; 7: 70 [PMID: 24109440 DOI: 10.3389/fnint.2013.00070]
91. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol 2013; 29: 79-84 [PMID: 23041678 DOI: 10.1097/MOG.0b013e32835a4b3e]
92. Gondalia SV, Palombo EA, Knowles SR, Cox SB, Meyer D, Austin DW. Molecular characterisation of gastrointestinal microbiota of children with autism (with and without gastrointestinal dysfunction) and their neurotypical siblings. Autism Res 2012; 5: 419-427 [PMID: 22997101 DOI: 10.1002/aur.1253]
93. Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL, Hansen RL, Phillips TM. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 2001; 49: 597-606 [PMID: 11357950 DOI: 10.1002/ana.1024]
94. Hautmann M, Friis UG, Desch M, Todorov V, Castrop H, Segerer F, Otto C, Schütz G, Schweda F. Pituitary adenylate cyclase-activating polypeptide stimulates renin secretion via activation of PAC1 receptors. J Am Soc Nephrol 2007; 18: 1150-1156 [PMID: 17360952 DOI: 10.1681/ASN.2006060633]
95. Burian B, Ortner A, Prassl R, Zimmer A, Mosgoeller W. Clinical potential of VIP by modified pharmaco-kinetics and delivery mechanisms. Endocr Metab Immune Disord Drug Targets 2012; 12: 344-350 [PMID: 23094831 DOI: 10.2174/1871 53012803832594]
96. Edvinsson L. Sensory nerves in man and their role in primary headaches. Cephalalgia 2001; 21: 761-764 [PMID: 11595008 DOI: 10.1046/j.1468-2982.2001.00245.x]
97. Gonzalez-Rey E, Varela N, Chorny A, Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr Pharm Des 2007; 13: 1113-1139 [PMID: 17430175 DOI: 10.2174/138161207780618966]
98. Samsam M, Coveñas R, Ahangari R, Yajeya J, Narváez JA. Role of neuropeptides in migraine; where do they stand in the latest expert recommendations in migraine treatment? Drug Devel Res 2007; 68: 298- 314 [DOI: 10.1002/ddr.20193]
99. Chandrasekharan B, Nezami BG, Srinivasan S. Emerging neuropeptide targets in inflammation: NPY and VIP. Am J Physiol Gastrointest Liver Physiol 2013; 304: G949-G957 [PMID: 23538492 DOI: 10.1152/ajpgi.00493.2012]
100. Kafitz KW, Rose CR, Thoenen H, Konnerth A. Neurotrophin-evoked rapid excitation through TrkB receptors. Nature 1999; 401: 918-921 [PMID: 10553907 DOI: 10.1038/44847]
101. Ray MT, Shannon Weickert C, Webster MJ. Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders. Transl Psychiatry 2014; 4: e389 [PMID: 24802307 DOI: 10.1038/tp.2014.26]
102. Scattoni ML, Martire A, Cartocci G, Ferrante A, Ricceri L. Reduced social interaction, behavioural flexibility and BDNF signalling in the BTBR T+ tf/J strain, a mouse model of autism. Behav Brain Res 2013; 251: 35-40 [PMID: 23270976 DOI: 10.1016/j.bbr.2012.12.028]
103. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010; 64: 341-357 [PMID: 20653908 DOI: 10.1111/j.1440-1819.2010.02113.x]
104. Taurines R, Segura M, Schecklmann M, Albantakis L, Grünblatt E, Walitza S, Jans T, Lyttwin B, Haberhausen M, Theisen FM, Martin B, Briegel W, Thome J, Schwenck C, Romanos M, Gerlach M. Altered peripheral BDNF mRNA expression and BDNF protein concentrations in blood of children and adolescents with autism spectrum disorder. J Neural Transm 2014; Epub ahead of print [PMID: 24500031]
105. Weidner KL, Buenaventura DF, Chadman KK. Mice overexpressing BDNF in forebrain neurons develop an altered behavioral phenotype with age. Behav Brain Res 2014; 268: 222-228 [PMID: 24768643 DOI: 10.1016/j.bbr.2014.04.025]
106. Singh KK, Park KJ, Hong EJ, Kramer BM, Greenberg ME, Kaplan DR, Miller FD. Developmental axon pruning mediated by BDNF-p75NTR-dependent axon degeneration. Nat Neurosci 2008; 11: 649-658 [PMID: 18382462 DOI: 10.1038/nn.2114]
107. Fouad K, Bennett DJ, Vavrek R, Blesch A. Long-term viral brain-derived neurotrophic factor delivery promotes spasticity in rats with a cervical spinal cord hemisection. Front Neurol 2013; 4: 187 [PMID: 24312075 DOI: 10.3389/fneur.2013.00187]
108. Jänisch W, Engel U, Leonhardt T. [Diffuse primary leptomeningeal gliomatosis]. Zentralbl Pathol 1991; 137: 523-530 [PMID: 1805932 DOI: 10.1038/sj.bjp.0707509]
109. Behrens MM, Strasser U, Lobner D, Dugan LL. Neurotrophin-mediated potentiation of neuronal injury. Microsc Res Tech 1999; 45: 276-284 [PMID: 10383120]
110. Buldyrev I, Tanner NM, Hsieh HY, Dodd EG, Nguyen LT, Balkowiec A. Calcitonin gene-related peptide enhances release of native brain-derived neurotrophic factor from trigeminal ganglion neurons. J Neurochem 2006; 99: 1338-1350 [PMID: 17064360 DOI: 10.1111/j.1471-4159.2006.04161.x]
111. Melemedjian OK, Tillu DV, Asiedu MN, Mandell EK, Moy JK, Blute VM, Taylor CJ, Ghosh S, Price TJ. BDNF regulates atypical PKC at spinal synapses to initiate and maintain a centralized chronic pain state. Mol Pain 2013; 9: 12 [PMID: 23510079 DOI: 10.1186/1744-8069-9-12]
112. Takeda M, Takahashi M, Kitagawa J, Kanazawa T, Nasu M, Matsumoto S. Brain-derived neurotrophic factor enhances the excitability of small-diameter trigeminal ganglion neurons projecting to the trigeminal nucleus interpolaris/caudalis transition zone following masseter muscle inflammation. Mol Pain 2013; 9: 49 [PMID: 24073832 DOI: 10.1186/1744-8069-9-49]
113. Samsam M, Coveñas R, Ahangari R, Yajeya J, Narváez JA, Tramu G. Simultaneous depletion of neurokinin A, substance P and calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion. Pain 2000; 84: 389-395 [PMID: 10666545 DOI: 10.1016/S0304-3959(99)00240-7]
114. Samsam M. Central nervous system acting drugs in treatment of migraine headache. Cent Nerv Syst Agents Med Chem 2012; 12: 158-172 [PMID: 22533510 DOI: 10.2174/187152412802430147]
115. Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, Trequattrini A, Palumbo R. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995; 15: 384-390 [PMID: 8536297 DOI: 10.1046/j.1468-29821995.1505384.x]
116. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350: 1104-1110 [PMID: 15014183 DOI: 10.1056/NEJMoa030505]
117. Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70: 1304-1312 [PMID: 17914062 DOI: 10.1212/01.WNL.0000286940.29755.61]